Forearm Immobilization in T2D
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorWageningen University
About this trial
The aim of the present study is to assess the impact of short-term forearm immobilization on forearm muscle glucose uptake and amino acid net balance and kinetics in individuals with T2D compared with a control group with normoglycaemia.
Eligibility criteria
Qualifiers
Males and females with or without diagnosed type 2 diabetes
Use lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2D
Aged 18-80 years at the time of signing informed consent
18.5 ≥ BMI ≤ 35 kg·m2
Disqualifiers
Type 1 or a genetic form of diabetes
Any diagnosed cardiovascular (heart) disease or high blood pressure (≥160 mmHg systolic and/or ≥100 mmHg diastolic)
Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors)
Consumption of a low-carbohydrate diet
Trial design
Treatments tested in this trial
- Forearm immobilization
Treatment groups
26 Participants
are divided into 2 treatment groupsLocations
1Wageningen University and Research6708WD, WageningenGelderland, Netherlands
Sponsors and collaborators
Wageningen University
Lead sponsor
Source ClinicalTrials.gov